VivoSeq
Other

T1DM

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

T1DM is an early-stage landscape with 0 programs across 2 companies. The most active players are AstraZeneca, GSK.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Completed7 · 70%
Unknown status1 · 10%
Terminated1 · 10%
Active, not recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Triple Therapy in T1DM
Active, not recruiting·SState University of New York at Buffalo·Phase 2/3·NCT03899402·78 enrolled
Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT01708044·32 enrolled
Faster Aspart on Insulin-pump Treated T1DM Patients
Completed·—·N/A·NCT04233203·48 enrolled
The Role of Amylin and Glucagon in T1DM
Completed·—·Phase 3·NCT00206258·30 enrolled
Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM
Completed·WWockhardt·Phase 1·NCT01357603·111 enrolled
Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting
Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·Phase 3·NCT03979352·28 enrolled
Subcutaneous Administration of Otelixizumab to T1DM Patients
Completed·GSK logoGSK·Phase 1·NCT00946257·33 enrolled
Insulin Dose Adjustments for Meals Differing in Fat Content in T1DM
Completed·NNorthumbria University·N/A·NCT02595658·10 enrolled
Siplizumab in T1DM
Terminated·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05574335·8 enrolled
DSME or DSME + MI in T1DM on Glycemic Control
Unknown status·MMahidol University·N/A·NCT03104829·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)